{{Drugbox
| verifiedrevid = 444061994
| IUPAC_name = 1'-[3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)propyl]spiro[1,5,6,7,8,8a-hexahydroimidazo[1,2-a]pyridine-3,4'-piperidine]-2-one
| image = Mosapramine.svg
| width = 250
| image2 = Mosapramine-xtal-1993-ball-and-stick.png
| width2 = 250

<!--Clinical data-->
| tradename = Cremin (クレミン, <small>[[Japan|JP]]</small>)
| Drugs.com = {{drugs.com|international|mosapramine}}
| pregnancy_category =  
| legal_status = Rx-only (<small>[[Japan|JP]]</small>)
| routes_of_administration = [[Mouth|Oral]] (tablets, oral solution)

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 89419-40-9
| ATC_prefix = N05
| ATC_suffix = AX10
| PubChem = 4257
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 04UZQ7O9SJ
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08235
| ChemSpiderID = 4107

<!--Chemical data-->
| C=28 | H=35 | Cl=1 | N=4 | O=1 
| molecular_weight = 479.057 g/mol
| smiles = C1CCN2C(C1)NC(=O)C23CCN(CC3)CCCN4C5=CC=CC=C5CCC6=C4C=C(C=C6)Cl
| StdInChI = 1S/C28H35ClN4O/c29-23-12-11-22-10-9-21-6-1-2-7-24(21)32(25(22)20-23)16-5-15-31-18-13-28(14-19-31)27(34)30-26-8-3-4-17-33(26)28/h1-2,6-7,11-12,20,26H,3-5,8-10,13-19H2,(H,30,34)
| StdInChIKey = PXUIZULXJVRBPC-UHFFFAOYSA-N
}}

'''Mosapramine''' ('''Cremin''') is an [[atypical antipsychotic]] used in [[Japan]].<ref>Takahashi N, Terao T, Oga T, Okada M. Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia. ''Neuropsychobiology''. 1999;39(2):81-5. {{PMID|10072664}}</ref> It is a potent [[dopamine antagonist]] with high affinity to the [[Dopamine receptor D2|D<sub>2</sub>]], [[Dopamine receptor D3|D<sub>3</sub>]], and [[Dopamine receptor D4|D<sub>4</sub>]] [[Receptor (biochemistry)|receptors]],<ref>Futamura T, Ohashi Y, Yano K, Takahashi Y, Haga K, Fukuda T. The affinities of mosapramine for the dopamine receptor subtypes in human cell lines expressing D2, D3 and D4 receptors. ''Nippon Yakurigaku Zasshi''. (Japanese) 1996 May;107(5):247-53. {{PMID|8690306}}</ref> and with moderate affinity for the [[5-HT2 receptor|5-HT<sub>2</sub> receptors]].<ref>Sumiyoshi T, Suzuki K, Sakamoto H, Yamaguchi N, Mori H, Shiba K, Yokogawa K. Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy. ''Neuropsychopharmacology''. 1995 Feb;12(1):57-64. {{DOI|10.1016/0893-133X(94)00064-7}} {{PMID|7766287}}</ref>

== See also ==
* [[Carpipramine]]
* [[Clocapramine]]
* [[Imidazopyridine]]

== References ==
{{Reflist}}

{{Antipsychotics}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Acetylcholine receptor modulators}}
{{Adrenergic receptor modulators}}
{{Dopamine receptor modulators}}
{{Histamine receptor modulators}}
{{Serotonin receptor modulators}}
}}
{{Tricyclics}}

[[Category:Atypical antipsychotics]]
[[Category:Dibenzazepines]]
[[Category:Lactams]]
[[Category:Chloroarenes]]
[[Category:Piperidines]]
[[Category:Pyridines]]
[[Category:Spiro compounds]]


{{nervous-system-drug-stub}}